Last reviewed · How we verify
Irinotecan-Eluting Beads
At a glance
| Generic name | Irinotecan-Eluting Beads |
|---|---|
| Also known as | DEBIRI |
| Sponsor | Federation Francophone de Cancerologie Digestive |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens (PHASE2)
- DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases (PHASE3)
- Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin (PHASE2)
- Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC (NA)
- Efficacy and Safety of DEB-BACE Combined With PD-1 Inhibitors in Stage II/III NSCLC With Standard Treatment Failure (NA)
- Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases (PHASE3)
- Study of the Practice of Debiri in France
- Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |